

09/077718  
12 Rec'd PCT/PTO 08 JUN 1998

1103326-0503


TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED OFFICE (DO/US)

<u>PCT/SE98/00907</u>	<u>15 May 1998</u>	<u>30 May 1997</u>
International Application Number	International Filing Date	Priority Date(s) Claimed

A NEW SALT  
Title of Invention

NYQVIST, Hakan and SOHN, Daniel D.

Applicant(s) for DO/US

"Express Mail" Label No. EF930634275US
Date of Deposit JUNE 8, 1998. I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231
 (Type or print name of person mailing paper or fee)
(Signature of person mailing paper or fee)

BOX PCT  
Assistant Commissioner for Patents  
Washington D.C. 20231

To the United States Designated Office (DO/US):

- I. Accompanying this transmittal letter are certain items which are required under 35 U.S.C. 371 in order that United States National processing of the above identified International application may commence:
- (X) at the expiration of the applicable time limit under PCT Articles 22 and 39(1) according to the provisions of 35 U.S.C. 371(b).
- ( ) as soon as possible upon receipt of this express request under 35 U.S.C. 371(f).

1. The U.S. National fee [35 U.S.C. 371(c)(1)]

a. ( ) was previously transmitted by applicant on (date)\_\_\_\_\_.

b. (X) is submitted herewith as follows:

<u>FOR</u>	<u>NO. FILED</u>	<u>NO. EXTRA</u>	<u>SMALL ENTITY</u>			<u>OTHER THAN</u>		
			<u>RATE</u>	<u>FEE</u>	<u>or</u>	<u>RATE</u>	<u>FEE</u>	
Basic Fee	(USPTO NOT ISA OR IPEA)		////	\$535	<u>or</u>	////	\$1070	
Total Claims	- 20 =	--	x11 =		<u>or</u>	x22 =		
Ind. Claims	3 - 3 =	--	x41 =		<u>or</u>	x82 =		
(X) Multiple Dependent Claim Presented			+135 =		<u>or</u>	+270 =	270	
<u>TOTAL</u>								
<u>NATIONAL FEE</u>				\$ _____	<u>or</u>		\$	

i. ( ) A check in the amount of \$ \_\_\_\_\_ is enclosed.

ii. (X) Please charge the filing fee, multiple dependent claim fee, and excess claims fee (if applicable) to Deposit Account No. 23-1703.

iii. (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-1703. A duplicate copy of this sheet is enclosed.

2. A copy of the International application as filed [35 U.S.C. 371(c)(2)]:

a. (X) is transmitted herewith.

b. ( ) is not required as the application was filed with the United States Receiving Office.

c. ( ) has been transmitted

i. ( ) by the International Bureau. Date of mailing of the application (from form PCT/IB/308): \_\_\_\_\_ A copy of form PCT/IB/308 is enclosed.

- ii. ( ) by applicant on (date) \_\_\_\_\_.
3. A translation of the International application into the English language [35 U.S.C. 371(c)(2)]:
- a. ( ) is transmitted herewith.
- b. (X) is not required as the application was filed in English.
- c. ( ) was previously transmitted by applicant on (date) \_\_\_\_\_.
4. Amendments to the claims of the International application under PCT Article 19 [35 U.S.C. 371(c)(3)]:
- a. ( ) are transmitted herewith.
- b. ( ) have been transmitted
- i. ( ) by the International Bureau. Date of mailing of the amendments (from form PCT/IB/308): \_\_\_\_\_.
- ii. ( ) by applicant on (date) \_\_\_\_\_.
- c. (X) have not been transmitted as
- i. ( ) no notification has been received that the International Searching Authority has received the Search Copy.
- ii. ( ) the Search Copy was received by the International Searching Authority but the Search Report has not yet issued. Date of receipt of Search Copy (from form PCT/ISA/202): \_\_\_\_\_.
- iii. ( ) applicant chose not to make amendments under PCT Article 19. Date of mailing of Search Report (from form PCT/ISA/210): \_\_\_\_\_.
- iv. (X) the time limit for the submission of amendments has not yet expired. The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.

5. A Translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)]:
- a. ☐ is transmitted herewith.
  - b. ☐ is not required as the amendments were made in the English language.
  - c. ☒ has not been transmitted for reasons indicated at point I.4.b. or c. above.
6. An oath or declaration of the inventor [35 U.S.C. 371(c)(4)] complying with 35 U.S.C. 115:
- a. ☐ was previously submitted by applicant on (date) \_\_\_\_\_
  - b. ☒ is submitted herewith;  
and such oath or declaration
    - i. ☒ is attached to the application.
    - ii. ☒ identifies the application and any amendments under PCT Article 19 which were transmitted as stated in points 1.2.b. or c. and 1.4. and states that they were reviewed by the inventor as required by 37 CFR 1.70.
  - c. ☐ will be submitted subsequently.

II. Concerning other documents:

1. An International Search Report or Declaration under PCT Article 17(2)(a):
- a. ☐ has been transmitted by the International Bureau. Date of mailing (from form PCT/IB/308): \_\_\_\_\_ A copy of form PCT/IB/308 is enclosed
  - b. ☐ is not required as the application was searched by the United States International Searching Authority.
  - c. ☐ A copy of the International Search Report is transmitted herewith.
  - d. ☐ has been submitted by applicant on (date) \_\_\_\_\_.

2. A Statement of prior art under 37 CFR 1.97 and 1.98:

- a. ☒ is transmitted herewith including copies of the references cited on the attached form PTO-1449. Also enclosed is a copy of the International-Type Search Report issued in the Swedish priority application.
- b. ☐ will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).
- c. ☐ was previously submitted by applicant on \_\_\_\_\_, in application serial no. \_\_\_\_\_.

3. ☒ An assignment is transmitted herewith for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

- a. ☒ Please charge the assignment recordation fee to Deposit Account No. 23-1703.
- b. ☐ A check in the amount of \$\_\_\_ is enclosed.

4. **Other document(s) or information included:**

- Copy of PCT/RO/101 - The PCT Request Form
- 2 sheets of formal drawings
- Information Disclosure Statement, PTO-1449, copy of the reference cited, and a copy of the International Type Search Report issued in the Swedish priority application.

Respectfully submitted,



Richard J. Sterner

Reg. No. 35,372

White & Case LLP  
Patent Department  
1155 Avenue of the Americas  
New York, NY 10036-2787

(212 ) 819-8200

enclosures

A new saltField of the Invention

- 5 The present invention relates to a new salt, namely (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen tartrate, particularly the (2*R*,3*R*) form of the tartrate and most particularly the monohydrate thereof. The invention also relates to processes for the manufacturing of the salt, the use of the salt in the manufacture of pharmaceutical formulations, to the use of the salt in medicine and methods of
- 10 treatment employing the salt particularly, in its monohydrate form.

Background of the Invention

- 15 The compound (*R*)-5-carbamoyl-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran, which also may be named (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide and pharmaceutically acceptable salts thereof are described in WO 95/11891.
- 20 The disclosed hydrochloride salt of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide is hygroscopic and thus physically instable during manufacturing as well as during storage.

Disclosure of the Invention

- 25 It has now surprisingly been found that the salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen tartrate, particularly the (2*R*,3*R*) form of the tartrate, in the anhydrous form or as the hemihydrate or monohydrate is physically more stable during storage than the hydrochloride salt of said compound, since the tartrate
- 30 forms of the compound are not disposed to absorb water to the same degree as the

hydrochloride salt of the same compound. This property of absorbing water is also a problem during storage and during manufacture of, e.g., solid pharmaceutical dosage forms such as tablets and hard gelatine capsules.

5 The good solubility and dissolution properties of the anhydrous tartrate salt are even more pronounced for the monohydrate of the tartrate salt, particularly the (2*R*,3*R*)-tartrate monhydrate. The water is firmly bound in the crystal lattice and is not released even upon heating up to 70 °C. This is well above the commonly used process temperatures, e.g., during the granulation process, in the production of tablets and hard gelatine capsules.

10 The good solubility and dissolution properties of the tartrate salt from, e.g., the oral drug delivery point of view, together with the low degree of hygroscopicity under normal humidity conditions makes the monohydrate form the most suitable form of the tartrate salt, and particularly the (2*R*,3*R*)-tartrate monohydrate from a quality assurance standpoint.

15 Thus, the monohydrate of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate, has surprisingly been shown to be physically stable under normal humidity conditions. To be suitable for long term storage and is easier to work with in the production of different solid pharmaceutical dosage forms.

20 Accordingly, the present invention relates to the salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen tartrate, particularly to the salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate and more particularly to the salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate  
25 monohydrate.

The present invention includes (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen tartrate, in the form of (2*R*,3*R*)-tartrate, (2*S*,3*S*)-  
30 tartrate and (2*R*,3*S*)-tartrate.

The salts of the invention may be used as selective 5-HT<sub>1A</sub> receptor antagonists in the treatment of CNS disorders and related medical disturbances. Examples of such disorders are depression, anxiety, obsessive-compulsive disorder (OCD), anorexia, bulimia, senile dementia, migraine, stroke, Alzheimer's disease, cognitive disorders, schizophrenia, especially cognitive dysfunction in schizophrenia, sleep disorders, urinary incontinence, premenstrual syndrome, hypertension and pain. Examples of such medical disturbances are thermoregulatory disturbances, sexual disturbances, disturbances in the cardiovascular system and disturbances in the gastrointestinal system.

The novel salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen tartrate, particularly the (2*R*,3*R*) form of the tartrate and most particularly the monohydrate of said tartrate salt exists preferably in substantially crystalline form may be formulated into various dosage forms for oral, parenteral, rectal and other modes of administrations.

Examples of formulations are tablets, pellets, granules, capsules (e.g. hard gelatine capsules), aqueous solutions and suspensions.

Usually the active ingredient will constitute from 0.0001 to 99% by weight of the formulation, more preferably from 0.001 to 30% by weight of the formulation.

To produce pharmaceutical formulations containing the active ingredient of the invention in the form of dosage units for oral applications, one may mix the active ingredient with a solid excipient, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, a cellulose derivative, a binder such as gelatine or polyvinylpyrrolidone, and a lubricant such as magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets. The active ingredient may be granulated together with excipients using an aqueous or organic solution of binders, and then dried and screened prior to tablet compression.



If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, e.g., gum arabic, gelatine, talcum, titanium dioxide, and the like. Alternatively, the tablet can be coated with a polymer known to a person skilled in the art, that is dissolved in a readily volatile organic solvent or mixture of organic solvents. Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different amounts of active ingredient.

For the preparation of hard gelatine capsules, the active ingredient may be processed in the form of granules, and may be admixed with the excipients mentioned above for tablets.

For the preparation of soft gelatine capsules, the active ingredient may be admixed with e.g. a vegetable oil or polyethylene glycol.

Suppositories for rectal administration may be prepared by dissolving or suspending the active ingredient in a molten suppository base such as Witepsol<sup>®</sup> followed by casting and cooling.

Gelatine rectal capsules may comprise the active ingredient in admixture with vegetable oil or paraffin oil and may contain some of the polymers and/or dyestuff mentioned above.

Aqueous solutions for parenteral or oral administration are produced by dissolving the active compound of the invention in water, adjusting the pH and ionic strength with common buffering agents such as citric acid, phosphoric acid or other similar acids or their commonly used salts; sodium carbonate, hydrogen carbonate or other similar salts; or hydrochloric acid or sodium hydroxide. In the case of parenteral solutions the sterility is ensured by final heat sterilization or, e.g., sterile filtration. Lyophilization, resulting in a reconstitutable solid product, may also be used.

Suitable daily doses of the salt of the invention in therapeutical treatment of humans are about 0.001-100 mg/kg body weight.

The specific processes for manufacturing (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (*2R,3R*)-tartrate, (*2S,3S*)-tartrate or (*2R,3S*)-tartrate, respectively, more specifically the monohydrate thereof, are a further aspect of the invention.

5

The process for manufacturing the new salt form (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (*2R,3R*)-tartrate, more specifically the monohydrate thereof, comprises the following consecutive steps:

- 10 i) dissolving (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide in an appropriate organic solvent, optionally by heating,
- ii) adding (*2R,3R*)-tartaric acid dissolved in an appropriate aqueous organic or non-aqueous organic solvent,
- 15 iii) allowing the obtained solution to stand cold in order to crystallize,
- iv) optionally, recrystallizing from an aqueous organic solvent, if a non-aqueous organic solvent is used in step ii), to obtain the tartrate monohydrate salt.

20

The corresponding (*2S,3S*)-tartrate and (*2R,3S*)-tartrate compound are manufactured by using (*2S,3S*)-tartaric acid and (*2R,3S*)-tartaric acid, respectively in step ii) above.

25

A more detailed description of the process of manufacturing is presented in Examples 1 and 2.

Starting from the anhydrous form or a mixture of the anhydrous form and the hemihydrate of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (*2R,3R*), (*2S,3S*) or (*2R,3S*)-tartrate, obtained by any suitable process,

recrystallization of the said tartrate from an appropriate aqueous organic solvent will give the monohydrate of the invention.

Appropriate solvents for dissolving (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide may be organic solvents such as tetrahydrofuran, diethyl ether, acetone, ethanol, methanol and other alcohols.

Appropriate aqueous organic solvents used in the crystallization or recrystallization may be alcohols, nitriles, esters, or ketones e. g. methanol, ethanol, isopropanol, acetonitrile, or acetone, preferably acetone.

### Example 1

#### **(*R*)-3-*N,N*-Dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide Hydrogen (2*R*,3*R*)-Tartrate**

(*R*)-3-*N,N*-Dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide (100 mg, 0.31 mmol) was dissolved in tetrahydrofuran (1 mL) by heating and the solution was diluted with diethyl ether (25 mL). To this solution was added a solution of (2*R*,3*R*)-tartaric acid made by dissolving 55 mg (0.35 mmol) of (2*R*,3*R*)-tartaric acid in tetrahydrofuran (1 mL) and diluting with diethyl ether (25 mL). The milky solution obtained was filtered and allowed to stand in the refrigerator overnight. The solid was filtered and dried in a vacuum oven to give the title compound in 142 mg white crystals (98% yield). Mp 174-180°C (DSC). Anal. Calcd. for C<sub>22</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>8</sub>: C, 56.4; H, 6.2; N, 6.0. Found: C, 56.2; H, 5.9; N, 5.6.

**Example 2****(*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide Hydrogen (2*R*,3*R*)-Tartrate Monohydrate**

(*R*)-3-*N,N*-Dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide (2.0 g, 6.3 mmol) was dissolved in tetrahydrofuran (5 mL) by heating and the solution was diluted with diethyl ether (400 mL). To this solution was added a solution of (2*R*, 3*R*)-tartaric acid made by dissolving 1.1 g (6.9 mmol) of (2*R*, 3*R*)-tartaric acid in tetrahydrofuran (15 mL) and diluting with diethyl ether (300 mL). The clear solution obtained was allowed to stand in the refrigerator over the weekend. The crystalline solid obtained was filtered and recrystallized from 1.5% aqueous acetone (400 mL) to give of the title compound 2.6 g sparkly crystals (85% yield). Mp. 174-180°C (DSC). Anal. Calcd. for C<sub>22</sub>H<sub>25</sub>FN<sub>2</sub>O<sub>9</sub>: C, 54.3; H, 6.4; N, 5.8. Found: C, 54.4; H, 6.3; N, 5.6.

**Analytical test method used on the products obtained in Examples 1 and 2**

The melting point (Mp) was measured by using differential scanning calorimetry (DSC).

**Establishment of water content****a) Thermogravimetric assay**

Thermogravimetric measurements performed showed that the anhydrous form of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate obtained in Example 1 had an initial weight loss of 0.997% w/w. The initial weight loss of 4.104% w/w for the monohydrate of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate obtained in Example 2 compared favourably with the theoretical water content of a monohydrate.

## b) X-Ray Diffraction

X-ray intensity data were collected on a single-crystal *MACH3/CAD4* diffractometer (Enraf-Nonius, 1994) equipped with graphite monochromatic CuK( $\alpha$ ) radiation and a proportional scintillation counter. The structure was solved by direct methods, *SIR92* (Altomare, Cascarano, Giacovazzo & Guagliardi, 1992) and refined with full-matrix least-square methods, *LSFM* (Hansen & Coppens, 1974), within the *MoLEN* software package (Straver & Schierbeck, 1994). All non-hydrogen atoms were refined anisotropically, whereas hydrogen atoms not involved in short intermolecular contacts were fixed from a late difference Fourier and supplied with isotropic displacement parameters,  $U_{\text{iso}} = 0.06 \text{ \AA}^2$ . Hydrogen atom positions involved in H-bonding were refined freely and assisted with a fixed isotropic temperature factor,  $U_{\text{iso}} = 0.06 \text{ \AA}^2$ , except for the crystal water hydrogens for which the factor used was  $U_{\text{iso}} = 0.07 \text{ \AA}^2$ .

Figure 1 shows the three-dimensional structure and absolute configuration of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide in relationship to the (2*R*,3*R*)-tartrate portion and the water molecule.

### Determination of stability

Moisture sorption of the monohydrate of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate compared to that of the anhydrous form of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate, as well as to that of the HCl-salt has been set as a measure of the relative physical stabilities of the respective products.

The moisture sorption analysis, absorption and desorption, respective was performed using a VTI microbalance, Model MB300W (VTI Corporation, USA) linked to an IBM PC. The relative humidity (RH) within the balance was monitored using a dew point analyser.

Approximately 10 mg of substance was dried to constant weight at 60°C and then exposed

stepwise to RHs of from 5 to 90% at 25°C, the step interval being 5%. The desorption profile was also obtained.

Figure 2 shows the moisture sorption curve of the HCl salt of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide. As seen from the figure, the HCl salt takes up a considerable amount of moisture at high relative humidities. At 85% relative humidity the HCl salt has taken up approximately 20% w/w and exhibits deliquescence.

Figure 2 also shows the moisture sorption curve of the anhydrous form (anhydrate) of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate. As seen from the figure, the anhydrous form (anhydrate) absorbs moisture readily. At a RH of 90%, about 4.2 % (w/w) moisture was absorbed. The desorption profile (the upper part of the curve) indicates that the moisture taken up is firmly bound and that the sample has formed a monohydrate.

Figure 2 shows the moisture sorption curve of the monohydrate of (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate. As seen from the figure the monohydrate absorbs only 2.5% (w/w) at 90% RH. Significant uptake of moisture was only recorded at RH of approximately 60% or above. The desorption profile shows that the moisture uptake is reversible.

## CLAIMS

1. A salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen tartrate.
2. A salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate.
3. The salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate monohydrate.
4. The salt according to any one of claims 1 to 3 in substantially crystalline form.
5. A pharmaceutical formulation containing, as active ingredient, the salt according to any one of claims 1 to 4 in association with a suitable diluent, excipient or an inert carrier.
6. A pharmaceutical formulation according to claim 5 for oral administration.
7. The salt according to any one of claims 1 to 4 for use in therapy.
8. The use of the salt according to any one of claims 1 to 4 in the manufacture of a medicament in the prevention or in the treatment of CNS disorders and related medical disturbances.
9. The use according to claim 8 in the manufacture of a medicament in prevention or in the treatment of 5-HT<sub>1A</sub> receptor antagonist activity related CNS disorders and medical disturbances.

10. The use according to claim 9 in the manufacture of a medicament in the prevention or in the treatment of depression.
11. The use according to claim 9 in the manufacture of a medicament in the prevention or in the treatment of anxiety.
12. A method for the prevention or the treatment of CNS disorders and related medical disturbances comprising administration, to a host in need of such treatment, an effective amount of the salt according to any one of claims 1 to 4.
13. A method according to claim 12 for prevention or the treatment of 5-HT<sub>1A</sub> receptor antagonist activity related CNS disorders and medical disturbances.
14. A method according to claim 13 for the prevention or the treatment of depression.
15. A method according to claim 13 for the prevention or the treatment of anxiety.
16. A process for the manufacture of the salt as defined in any one of claims 1 to 4 characterized by the following consecutive steps:
  - i) dissolving (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide in an appropriate solvent, optionally by heating,
  - ii) adding (*2R, 3R*)-, (*2S, 3S*)- or (*2R, 3S*)-tartaric acid, respectively, dissolved in an appropriate aqueous organic solvent or non-aqueous organic solvent,
  - iii) allowing the solution obtained to stand cold to crystallize,



iv) optionally recrystallizing in an appropriate aqueous organic solvent, if a non-aqueous organic solvent is used in step ii), to obtain the salt defined in any one of claims 3 or 4.

5 17. A process for the manufacture of the salt as defined in claims 3 to 4 characterized by recrystallizing (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3, 4-dihydro-2*H*-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-, (2*S*,3*S*)- or (2*R*,3*S*)-tartrate in an appropriate aqueous organic solvent.

10 18. A process according to any one of the claims 16 or 17, wherein the aqueous organic solvent is aqueous acetone.

15

20

25


30

### Abstract

A new salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen tartrate, particularly the (2*R*,3*R*)-tartrate thereof, most particularly the (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate monohydrate, processes for the manufacture of said tartrate salt, the use of the salt in medicine, the use of the tartrate salt in the manufacture of pharmaceutical formulations, and a method for the treatment of CNS disorders by administration of the tartrate salt to a host in need of such treatment.


1 / 2

Fig. 1



2 / 2

Fig. 2



Docket Number:

**DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled A NEW SALT, the specification of which is attached hereto unless the following box is checked:

☒ was filed on 15 May 1998 as United States Application Number or PCT International Application Number SE98/00907 and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

9702066-3  
(Number)

Sweden  
(Country)

30 May 1997  
(Day/Month/Year Filed)

\_\_\_\_\_  
(Number)

\_\_\_\_\_  
(Country)

\_\_\_\_\_  
(Day(Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

\_\_\_\_\_  
(Application Number)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Number)

\_\_\_\_\_  
(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Application Number)

(Filing Date)

(Status -- patented, pending, abandoned)

(Application Number)

(Filing Date)

(Status -- patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Edward V. Filardi, Reg. No. 25,757; Nels T. Lippert, Reg. No. 25,888; Dimitrios Drivas, Reg. No. 32,218; Robert B. Smith, Reg. No. 28,538; Cecilia O'Brien Lofters, Reg. No. 33,434; David Bender, Reg. No. 35,445; Richard J. Sterner, Reg. No. 35,372; Hans-Peter G. Hoffmann, Reg. No. 37,352; Thelma A. Chen Cleland, Reg. No. 40,948; Scott T. Weingartner, Reg. No. 37,756; Leslie Morioka, Reg. No. 40,304; John R. Witcher, III, Reg. No. 39,877; and John Scheibeler, Reg. No. 35,346 all of the firm of WHITE & CASE L.L.P., with offices at 1155 Avenue of the Americas, New York, New York 10036,  
Address all telephone calls to \_\_\_\_\_ at telephone number (212) 819-8200  
Address all correspondence to WHITE & CASE L.L.P.

Patent Department  
1155 Avenue of the Americas  
New York, NY 10036-2787

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor  
(given name, family name)

Håkan Nyqvist

Inventor's signature

Håkan Nyqvist

Date:

25 May 1998

Residence Address

Astra Arcus AB, S-151 85 Södertälje, Sweden

Citizenship

Sweden


Post Office Address

Astra Arcus AB, S-151 85 Södertälje, Sweden

Full name of second joint inventor, if any  
(given name, family name)

2-00  
Daniel D Sohn

Second inventor's signature



Date

25 May 1998

Residence Address

Astra Arcus AB, S-151 85 Södertälje, Sweden

SEX Citizenship

USA

Post Office Address

Astra Arcus AB, S-151 85 Södertälje, Sweden